Mind Medicine to be added to Nasdaq Biotechnology Index December 23.

Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23. “2024 has been a transformational year for MindMed. We’ve successfully executed many important milestones, including raising approximately $250M through two equity financings, obtaining a newly issued patent covering MM120 orally disintegrating tablet ODT and extending intellectual property protection through 2041, expanding our pipeline to include MM120 ODT for major depressive disorder, and most recently, launching Voyage, our Phase 3 study of MM120 ODT in generalized anxiety disorder,” said Rob Barrow, Chief Executive Officer of MindMed. “We are in a pivotal phase in our growth and the addition to the NBI further validates our potential in delivering long-term value to shareholders as we progress our pipeline and aim to deliver transformational innovation for people living with brain health disorders.” The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Marke that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark ICB . The NBI is calculated under a modified capitalization-weighted methodology. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.